28 results on '"López Bernaldo de Quirós, Juan Carlos"'
Search Results
2. Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015
- Author
-
Iribarren, José Antonio, Rubio, Rafael, Aguirrebengoa, Koldo, Arribas, Jose Ramón, Baraia-Etxaburu, Josu, Gutiérrez, Félix, Lopez Bernaldo de Quirós, Juan Carlos, Losa, Juan Emilio, Miró, José M<ce:sup loc='post">a</ce:sup>, Moreno, Santiago, Pérez Molina, José, Podzamczer, Daniel, Pulido, Federico, Riera, Melchor, Rivero, Antonio, Sanz Moreno, José, Amador, Concha, Antela, Antonio, Arazo, Piedad, Arrizabalaga, Julio, Bachiller, Pablo, Barros, Carlos, Berenguer, Juan, Caylá, Joan, Domingo, Pere, Estrada, Vicente, Knobel, Hernando, Locutura, Jaime, López Aldeguer, José, Llibre, Josep M<ce:sup loc='post">a</ce:sup>, Lozano, Fernando, Mallolas, Josep, Malmierca, Eduardo, Miralles, Celia, Miralles, Pilar, Muñoz, Agustín, Ocampo, Agustín, Olalla, Julián, Pérez, Inés, Pérez Elías, M<ce:sup loc='post">a</ce:sup> Jesús, Pérez Arellano, José Luis, Portilla, Joaquín, Ribera, Esteban, Rodríguez, Francisco, Santín, Miguel, Sanz Sanz, Jesús, Téllez, M<ce:sup loc='post">a</ce:sup> Jesús, Torralba, Miguel, Valencia, Eulalia, and Von Wichmann, Miguel Angel
- Published
- 2016
- Full Text
- View/download PDF
3. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1
- Author
-
Mothe, Beatriz, Climent, Nuria, Plana, Montserrat, Rosàs, Miriam, Jiménez, José Luis, Muñoz-Fernández, María Ángeles, Puertas, María C., Carrillo, Jorge, Gonzalez, Nuria, León, Agathe, Pich, Judit, Arnaiz, Joan Albert, Gatell, Jose M., Clotet, Bonaventura, Blanco, Julià, Alcamí, José, Martinez-Picado, Javier, Alvarez-Fernández, Carmen, Sánchez-Palomino, Sonsoles, Guardo, Alberto C., Peña, José, Benito, José M., Rallón, Norma, Gómez, Carmen E., Perdiguero, Beatriz, García-Arriaza, Juan, Esteban, Mariano, López Bernaldo de Quirós, Juan Carlos, Brander, Christian, García, Felipe, Mothe, Beatriz, Cobarsi, Patricia, Rosàs, Miriam, Puertas, María C., Carrillo, Jorge, Blanco, Juliá, Martinez-Picado, Javier, Clotet, Bonaventura, Brander, Christian, Climent, Nuria, Plana, Montserrat, Alvarez, Carmen, Sánchez, Sonsoles, León, Agathe, Pich, Judit, Arnaiz, Joan Albert, Leal, Lorna, Torres, Berta, Lucero, Constanza, Guardo, Alberto C., Gatell, Jose M., García, Felipe, Jiménez, José Luis, Muñoz-Fernández, María Angeles, López Bernaldo de Quirós, Juan Carlos, Esteban, Mariano, Gómez, Carmen Elena, Perdiguero, Beatriz, García-Arriaza, Juan, Cepeda, Victoria, Sánchez-Sorzano, Carlos Oscar, Gonzalez, Nuria, Alcamí, José, Jiménez, Laura, Benito, José M., Rallón, Norma, and Peña, José
- Published
- 2015
- Full Text
- View/download PDF
4. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015
- Author
-
Iribarren, José Antonio, Rubio, Rafael, Aguirrebengoa, Koldo, Arribas, Jose Ramón, Baraia-Etxaburu, Josu, Gutiérrez, Félix, Lopez Bernaldo de Quirós, Juan Carlos, Losa, Juan Emilio, Miró, José M<ce:sup loc='post">a</ce:sup>, Moreno, Santiago, Pérez Molina, José, Podzamczer, Daniel, Pulido, Federico, Riera, Melchor, Rivero, Antonio, Sanz Moreno, José, Amador, Concha, Antela, Antonio, Arazo, Piedad, Arrizabalaga, Julio, Bachiller, Pablo, Barros, Carlos, Berenguer, Juan, Caylá, Joan, Domingo, Pere, Estrada, Vicente, Knobel, Hernando, Locutura, Jaime, López Aldeguer, José, Llibre, Josep M<ce:sup loc='post">a</ce:sup>, Lozano, Fernando, Mallolas, Josep, Malmierca, Eduardo, Miralles, Celia, Miralles, Pilar, Muñoz, Agustín, Ocampo, Agustín, Olalla, Julián, Pérez, Inés, Pérez Elías, M<ce:sup loc='post">a</ce:sup> Jesús, Pérez Arellano, José Luis, Portilla, Joaquín, Ribera, Esteban, Rodríguez, Francisco, Santín, Miguel, Sanz Sanz, Jesús, Téllez, M<ce:sup loc='post">a</ce:sup> Jesús, Torralba, Miguel, Valencia, Eulalia, and Von Wichmann, Miguel Angel
- Published
- 2016
- Full Text
- View/download PDF
5. SARS-COV-2 Infection in People Living with HIV: Experience from a Tertiary Hospital in Madrid.
- Author
-
González Guembe, Maria, Tisner Pensado, Yago, Tejerina Picado, Francisco, Diez, Cristina, Pérez Latorre, Leire, Fanciulli, Chiara, Parras Vázquez, Francisco, López Bernaldo de Quirós, Juan Carlos, Berenguer, Juan, Padilla Ortega, Belen, Machado, Marina, Valerio Minero, Maricela, Muñoz Garcia, Patricia, Bouza Santiago, Emilio, Galar, Alicia, Catalan, Pilar, Alonso, Roberto, Bellón, Jose M, Aldámiz-Echevarría Lois, Teresa, and Adán-Jiménez
- Abstract
Since SAR-COV-2 infection emerged and spread worldwide, little is known about its impact on people living with human immunodeficiency virus (HIV). We performed a single-center retrospective study to describe the potential particularities and risk factors for respiratory failure (RF) in that population. This single-center retrospective study included patients infected with HIV, whose current follow-up is run in this center, above18 years of age, with diagnosis of SARS-CoV-2 infection between March 5, 2020 and April 15, 2021. We collected data regarding HIV immunological and virological status, main epidemiological characteristics, as well as those conditions considered to potentially influence in SARS-CoV-2 evolution; and clinical, microbiological, radiological, respiratory status, and survival concerning coronavirus disease 2019 (COVID-19). We compared all that, for patients with and without RF and performed a logistic regression for suspected risk factors for RF. One hundred seventy-seven HIV patients were diagnosed from COVID-19 (mean age 53.8 years, 81.3% male). At diagnosis, 95.5% were receiving ART and 91.3% had undetectable viral load, with median CD4 count of 569 cells/μL. One hundred thirty-eight patients (78.4%) had symptoms, 44 (25%) developed RF and 53 (31%) developed bilateral pneumonia. The most commonly used treatments were: steroids (26.7%) and hydroxychloroquine (13.1%). When comparing patients with and without RF, we found statistically significant differences for 20 of the analyzed variables such as age (p < .001) and CD4 (p 0.002), and route of HIV transmission by intravenous drug users IVDU (p 0.002) were determined. In multivariate analysis, age [odds ratio (OR) 1.095] and CD4 count less than 350 cells/μL (OR 3.36) emerged as risk factor for RF. People living with HIV whose CD4 count is <350 cells are at higher risk of developing RF when infected by SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Frailty, markers of immune activation and oxidative stress in HIV infected elderly
- Author
-
Álvarez, Susana, primary, Brañas, Fátima, additional, Sánchez-Conde, Matilde, additional, Moreno, Santiago, additional, López-Bernaldo de Quirós, Juan Carlos, additional, and Muñoz-Fernández, Mª Ángeles, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Virological outcome measures during analytical treatment interruptions in chronic HIV-1 infected patients
- Author
-
Fehér, Csaba, primary, Leal, Lorna, additional, Plana, Montserrat, additional, Climent, Nuria, additional, Crespo Guardo, Alberto, additional, Martínez, Esteban, additional, Castro, Pedro, additional, Díaz-Brito, Vicens, additional, Mothe, Beatriz, additional, López Bernaldo De Quirós, Juan Carlos, additional, Gatell, Josep María, additional, Aloy, Patrick, additional, and García, Felipe, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B
- Author
-
Couto, Elvira, primary, Diaz-Brito, Vicenç, additional, Mothe, Beatriz, additional, Guardo, Alberto C., additional, Fernandez, Irene, additional, Ugarte, Ainoa, additional, Etcheverry, Flor, additional, Gómez, Carmen E., additional, Esteban, Mariano, additional, Pich, Judit, additional, Arnaiz, Joan Albert, additional, López Bernaldo de Quirós, Juan Carlos, additional, Brander, Christian, additional, Plana, Montserrat, additional, García, Felipe, additional, and Leal, Lorna, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study.
- Author
-
Ruiz-Algueró, Marta, Hernando, Victoria, Marcos, Henar, Gutiérrez, Gonzalo, Pérez-Elías, Maria Jesus, López-Bernaldo de Quirós, Juan Carlos, Pulido, Federico, Górgolas, Miguel, Sanz, Jesus, Suarez-García, Ines, Fernandez, Maria Teresa, Losa, Juan Emilio, Pérez, Jose Luis, Ladrero, Maria Oliva, Prieto, Miguel Ángel, González, Gustavo, Izquierdo, Ana, Viloria, Luis Javier, López, Irene, and Martínez, Eva
- Subjects
HIV infections ,HIV ,QUALITY of life ,VIRAL load ,CROSS-sectional method - Abstract
Background: HIV infection has become a chronic disease and well-being of people living with HIV (PLHIV) is now of particular concern. The objectives of this paper were to describe self-rated health among PLHIV, on ART and on ART virally suppressed and to analyse its determinants.Methods: Data were obtained from a second-generation surveillance system based on a cross-sectional one-day survey in public hospitals. Epidemiological and clinical data were collected among HIV-infected inpatients and outpatients receiving HIV-related care the day of the survey in 86 hospitals in 2019. Self-rated health was measured using a question included in the National Health Survey: "In the last 12 months, how would you rate your health status?" an ordinal variable with five categories (very good, good, moderate, bad and very bad). For the analysis, these responses were dichotomized into two categories: 1 = very good/good and 0 = moderate, bad or very bad health status. Factors associated with very good/good self-rated health were estimated using logistic regression.Results: Of 800 PLHIV, 67.5% perceived their health as very good/good, 68.4% among PLHIV on ART and 71.7% of those virally suppressed. Having university education (adjusted odds ratio (aOR):2.1), being unemployed (aOR:0.3) or retired (aOR:0.2), ever being diagnosed of AIDS (aOR:0.6), comorbidities (aOR:0.3), less than 2 year since HIV diagnosis (aOR:0.3) and not receiving ART (aOR:0.3) were associated with good self-rated health. Moreover, among PLHIV on ART, viral load less than 200 copies (aOR:3.2) were related to better perceived health. Bad adherence was inversely associated with good self-rated health among PLHIV on ART (aOR:0.5) and of those virally suppressed (aOR:0.4).Conclusions: Nearly seven in 10 PLHIV in Spain considered their health status as very good/good, being higher among virally suppressed PLHIV. Both demographic and clinical determinants affect quality of life. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
- Author
-
Crespo Guardo, Alberto, Gómez, Carmen Elena, Díaz Brito, Vicens, Pich, Judit, Arnaiz Gargallo, Juan Alberto, Perdiguero, Beatriz, García Arriaza, Juan, GonzÁlez, Núria, Sorzano, Carlos O. S., Jiménez, Laura, Jiménez, José Luis, Muñoz Fernández, María Ángeles, Gatell, José M., Alcamí, José, Esteban, Mariano, López Bernaldo de Quirós, Juan Carlos, García Alcaide, Felipe, Plana Prades, Montserrat, RISVAC02boost study, Instituto de Salud Carlos III, and Institut d’Investigacions Biomédiques August Pi I Sunyer
- Subjects
0301 basic medicine ,RNA viruses ,CD4-Positive T-Lymphocytes ,Physiology ,viruses ,Human immunodeficiency virus (HIV) ,lcsh:Medicine ,Antibody Response ,CD8-Positive T-Lymphocytes ,HIV Antibodies ,medicine.disease_cause ,Pathology and Laboratory Medicine ,Biochemistry ,Placebos ,White Blood Cells ,Immunodeficiency Viruses ,Animal Cells ,Immune Physiology ,Healthy volunteers ,Medicine and Health Sciences ,Medicine ,Public and Occupational Health ,Enzyme-Linked Immunoassays ,Sida ,lcsh:Science ,Immune Response ,AIDS Vaccines ,Multidisciplinary ,Immune System Proteins ,biology ,T Cells ,MVA-B ,Flow Cytometry ,Vaccination and Immunization ,Healthy Volunteers ,Cèl·lules T ,Medical Microbiology ,Viral Pathogens ,Viruses ,Cellular Types ,Pathogens ,Research Article ,Immune Cells ,Immunology ,T cells ,Immunization, Secondary ,Cytotoxic T cells ,Enzyme-Linked Immunosorbent Assay ,Research and Analysis Methods ,complex mixtures ,Microbiology ,Antibodies ,03 medical and health sciences ,Immune system ,Vacunes antivíriques ,Retroviruses ,VIH (Virus) ,Humans ,Immunoassays ,Microbial Pathogens ,Blood Cells ,business.industry ,HIV (Viruses) ,Viral vaccines ,lcsh:R ,Lentivirus ,Organisms ,Biology and Life Sciences ,Proteins ,HIV ,Correction ,Cell Biology ,biology.organism_classification ,Virology ,Antibodies, Neutralizing ,030104 developmental biology ,Immunization ,Immunologic Techniques ,HIV-1 ,lcsh:Q ,Preventive Medicine ,business - Abstract
BACKGROUND: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost. METHODS: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost. RESULTS: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively. CONCLUSIONS: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector. TRIAL REGISTRATION: ClinicalTrials.gov NCT01923610. This study was partially supported by grants: FIS PI12/00969, PI15/00480, SAF2015-66193-R., EC10-153, TRA-094, RIS, HIVACAT, SAF2013-45232-R. RIS: Red Temática Cooperativa de Grupos de Investigación en Sida del Fondo de Investigación Sanitaria (FIS). HIVACAT: HIV development program in Catalonia. IDIBAPS: Institut d’Investigacions Biomèdiques August Pi I Sunyer. Sí
- Published
- 2016
11. Frailty and physical function in older HIV-infected adults
- Author
-
Brañas, Fatima, primary, Jiménez, Zaida, additional, Sánchez-Conde, Matilde, additional, Dronda, Fernando, additional, López-Bernaldo De Quirós, Juan Carlos, additional, Pérez-Elías, María J., additional, Miralles, Pilar, additional, Ramírez, Margarita, additional, Moreno, Ana, additional, Berenguer, Juan, additional, and Moreno, Santiago, additional
- Published
- 2017
- Full Text
- View/download PDF
12. A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
- Author
-
Gómez, Carmen Elena, primary, Perdiguero, Beatriz, additional, García-Arriaza, Juan, additional, Cepeda, Victoria, additional, Sánchez-Sorzano, Carlos Óscar, additional, Mothe, Beatriz, additional, Jiménez, José Luis, additional, Muñoz-Fernández, María Ángeles, additional, Gatell, Jose M., additional, López Bernaldo de Quirós, Juan Carlos, additional, Brander, Christian, additional, García, Felipe, additional, and Esteban, Mariano, additional
- Published
- 2015
- Full Text
- View/download PDF
13. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
- Author
-
C. Guardo, Alberto, Gómez, Carmen Elena, Díaz-Brito, Vicens, Pich, Judit, Arnaiz, Joan Albert, Perdiguero, Beatriz, García-Arriaza, Juan, González, Nuria, Sorzano, Carlos O. S., Jiménez, Laura, Jiménez, José Luis, Muñoz-Fernández, María Ángeles, Gatell, José M, Alcamí, José, Esteban, Mariano, López Bernaldo de Quirós, Juan Carlos, García, Felipe, Plana, Montserrat, and null, null
- Subjects
VACCINES ,AIDS vaccines ,IMMUNE response ,HUMORAL immunity ,IMMUNIZATION ,ANTIBODY formation ,T cells - Abstract
Background: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost. Methods: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost. Results: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1
st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively. Conclusions: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector. Trial registration: ClinicalTrials.gov . [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
14. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences
- Author
-
Santos, José Ramón, primary, Blanco, José Luis, additional, Masiá, Mar, additional, Gutiérrez, Félix, additional, Pérez-Elías, María Jesús, additional, Iribarren, José Antonio, additional, Force, Lluis, additional, Antela, Antonio, additional, Knobel, Hernando, additional, Salavert, Miguel, additional, López Bernaldo De Quirós, Juan Carlos, additional, Pino, María, additional, Paredes, Roger, additional, and Clotet, Bonaventura, additional
- Published
- 2015
- Full Text
- View/download PDF
15. Colaboradores
- Author
-
Abalovich, Marcos S., Agustí García-Navarro, Álvaro, Agustí García-Navarro, Carlos, Albanell Mestres, Joan, Alcalá Hernández, Luis, Alcaraz Asensio, Antonio, Alcázar Arroyo, Roberto, Alegre de Miquel, Víctor, Alexandra Hanzu, Felicia, Almirante Gragera, Benito, Alonso Tarrés, Carles, Alsina Gibert, Mercè, Alsina Manrique de Lara, Laia, Álvarez Martínez, Miriam José, Álvarez-Sala Walther, José Luis, Ambrosioni Czyrko, Juan, Ancochea Bermúdez, Julio, Andrade Bellido, Raúl J., Antón López, Jordi, Aran Perramon, Josep Maria, Arance Fernández, Ana, Arboleya Rodríguez, Luis, Arellano Tolivar, Antonio, Arias Gómez, Manuel, Arias Loste, M.ª Teresa, Ariza Cardenal, Javier, Armengol Dulcet, Lluís, Aróstegui Gorospe, Juan Ignacio, Arrese, Marco, Arroyo Pérez, Vicente, Aschner Montoya, Pablo, Audí Parera, Laura, Azpiroz Vidaur, Fernando, Badimon Maestro, Lina, Baena Caparrós, Jacinto, Ballester Rodés, Eugenio, Ballina García, Francisco Javier, Barberà Mir, Joan Albert, Barberán López, José, Barile Fabris, Leonor, Bartra Tomás, Joan, Bassas Arnau, Lluís, Bassat Orellana, Quique, Bataller Alberola, Luis, Bayés Colomer, Mónica, Bernardo Arroyo, Miquel, Berraondo López, Pedro, Bielsa Marsol, Isabel, Bladé Creixentí, Joan, Blancafort Sansó, Xavier, Blanco Arévalo, José Luis, Blanco García, Francisco J., Blanes Mompó, José Ignacio, Blesa González, Rafael, Bodegas Cañas, Andrés Ignacio, Bodro Marimont, Marta, Boronat Guerrero, Susana, Bosch Albareda, Francesc, Bosch Genover, Jaime, Bosch Genover, Xavier, Bosch Gil, José Ángel, Bosch Mestres, Jordi, Botey Puig, Albert, Bouza Santiago, Emilio, Bru Saumell, Concepció, Brugada Terradellas, Josep, Brugada Terradellas, Ramon, Bruguera Cortada, Miquel, Bruix Tudó, Jordi, Bujanda Fernández de Piérola, Luis, Buti Ferret, María, Caballería Rovira, Joan, Cabellos Mínguez, Carmen, Cahn, Pedro, Calvet Calvo, Xavier, Calzado Isbert, Sonia, Campins Martí, Magda, Campistol Plana, Josep M.ª, Campo Casanelles, Miguel del, Campo Güerri, Elías, Campuzano Larrea, Óscar, Campuzano Uceda, Victoria, Cardellach López, Francesc, Carmena Rodríguez, Rafael, Carmona Herrera, Francisco, Carracedo Álvarez, Ángel, Carrascosa Lezcona, Antonio, Carreres Molas, Anna, Carreras Pons, Enric, Casabona i Barbarà, Jordi, Casademont Pou, Jordi, Casanueva, Felipe F., Cases Amenós, Aleix, Castells Garangou, Antoni, Castro Fornieles, Josefina, Castro Rebollo, Pedro, Catalán Eraso, Beatriz, Caylà Buqueras, Joan A., Cervantes Requena, Francisco, Cervera Segura, Ricardo, Cervera Álvarez, Carlos, Chamorro Sánchez, Ángel, Cinta Cid Xutglà, María, Cinca Cuscullola, Juan M.ª, Coll Daroca, Joaquím, Coll Rosell, M.ª José, Colmenero Arroyo, Jordi, Conesa Bertrán, Gerardo, Corell Almuzara, Alfredo, Crespo Casal, Manuel, Crespo Conde, Gonzalo, Crespo García, Javier, Cristòfol Allué, Ramon, Cubiella Fernández, Joaquín, Cuenca Estrella, Manuel, Dalmau Obrador, Josep, Davant Llauradó, Ester, Delgado González, Julio, Desola Alà, Jordi, Diekmann, Fritz, Dolz Abadía, Carlos, Domínguez Benítez, José Antonio, Domínguez García, Ángela, Domínguez Luengo, Carmen, Domínguez Luzón, M.ª Ángeles, Domínguez Tordable, M.ª Jesús, Dopazo Blázquez, Joaquín, Dueñas Laita, Antonio, Durán Rebolledo, Carlos Eduardo, Duró Pujol, Juan Carlos, Echevarría Mayo, José Manuel, Echevarria Mayo, Juan Emilio, Eiros Bouza, José M.ª, Elizalde Frez, José Ignacio, Engel Rocamora, Pablo, Enrique Cahn, Pedro, Enríquez de Salamanca Lorente, Rafael, Escorsell Mañosa, Àngels, Escribano Mora, Luis, Estapé Madinabeitia, Tania, Estapé Rodríguez, Jordi, Esteban Mur, Rafael, Esteller Badosa, Manel, Esteve Comas, María, Esteve Pardo, María, Esteve Reyner, Jordi, Estivill Pallejà, Xavier, Estruch Riba, Ramón, Fainboim, Leo, Feliu Frasnedo, Evarist, Fernández Bañares, Fernando, Fernández Fernández, Óscar, Fernández Gómez, Javier, Fernández-Tresguerres Hernández, Jesús Ángel, Ferrándiz Foraster, Carlos, Ferrer Monreal, Miguel, Figuerola Pino, Daniel, Fillat Fonts, Cristina, Fonollosa Pla, Vincent, Fonseca Capdevila, Eduardo, Font Creus, Bernat, Fontanellas Romá, Antonio, Forns Bernhardt, Xavier, Fortuny Guasch, Claudia, Franco de Castro, Agustín, Franco Vásquez, José G., Fresno Escudero, Manuel, Galarza Delgado, Dionicio Ángel, Galicia Paredes, Miguel, Gállego Culleré, Montserrat, Gallego García de Vinuesa, Pastora, Gárate Ormaechea, Teresa, García Lareo, Manuel, Carlos García Moncó, Juan, García Nieto, Víctor M., García-Pagán, Juan Carlos, García Sánchez, José Elías, García-Zepeda, Eduardo Alberto, Garrido Marín, Eduardo, Gascón Brustenga, Joaquim, Gatell Artigas, Josep M.ª, Gaztambide Sáenz, Sonia, Giavina-Bianchi, Pedro, Gil de Extremera, Blas, Giménez Pérez, Montserrat, Ginès Gibert, Pere, Girós Blasco, M.ª Luisa, Goday Arnó, Albert, Gómez Dantés, Héctor, Gómez Gil, Esther, Gómez Junyent, Joan, Gómez Sáez, José Manuel, Gómez-Batiste Alentorn, Xavier, Gomollón García, Fernando, González Argenté, Francesc Xavier, González Juanatey, José Ramón, González Macías, Jesús, González Martín, Julià, González Tugas, Matías, Gonzalo de Liria, Carlos Rodrigo, Gracia Guillén, Diego, Gracia Roldán, Javier de, Grau Junyent, Josep M.ª, Grau de Castro, Juan José, Graus Ribas, Francesc, Gual Solé, Antoni, Guañabens Gay, Núria, Guardiola Ponti, Helena, Gurguí Ferrer, Mercè, Gutiérrez Julián, José M.ª, Gutiérrez Ponce de León, Fernando, Halperin Rabinovich, Irene, Hawkins Carranza, Federico G., Hernández García, Miguel T., Hernández-Nieto, Luis, Herrero Santos, José Ignacio, Ibáñez Toda, Lourdes, Illa Sendra, Isabel, Iranzo de Riquer, Alejandro, Jaraquemada Pérez de Guzmán, Dolores, Jové Teixidó, Josep, Juan Otero, Manel, Juanola Roura, Xavier, Kalil, Jorge, Khamashta, Munther, Labarca Labarca, Jaime, Laborde, Amalia, Lanas Arbeloa, Ángel, Larrosa Escartín, Nieves, Liñares Louzao, Josefina, Lobo Satué, Antonio, Londoño, María Carlota, López Bernaldo de Quirós, Juan Carlos, López Guillermo, Armando, López Otín, Carlos, Luis López-Sendón, José, López-Vélez Pérez, Rogelio, Lozano Sánchez, Francisco S., Lozano Soto, Francisco, Lucas Martín, Anna M.ª, Lucas Morante, Tomás, Luis Alonso, Pedro, Lumbreras Bermejo, Carlos, Madaria Pascual, Enrique de, Mallolas Masferrer, Josep, Mañá Rey, Juan, Marcas Vila, Álex, Marco Reverté, Francesc David, Marcos Maeso, M.ª Ángeles, Marrades Sicart, Ramón M.ª, Marruecos Sant, Lluís, Marrugat de la Iglesia, Jaume, Martín Sierra, Cristina, Martínez Díaz-Guerra, Guillermo, Martínez Martínez, José Antonio, Martínez Vea, Alberto, Martínez Yélamos, Sergio, Martínez Yoldi, Miguel J., Martorell Pons, Jaume, Mas Capó, Jordi, Mas Ordeig, Antoni, Masana Marín, Lluís, Masana Montejo, Guillem, Manuel Mascaró Galy, José, Matas Andreu, Lurdes, Maurel, Joan, Melero, Marcelo José, Melero Bermejo, Ignacio, Mellado González, Begoña, Mensa Pueyo, José, Mercé Klein, Jordi, Mestres Alomar, Gaspar, Milà Recasens, Monteserrat, Miquel Abbad, Carlos, Miralles Basseda, Ramón, Miralles Hernández, Manuel, Miró Meda, José M.ª, Mòdol Deltell, Josep M.ª, Molero Richard, Xavier, Molina Infante, Javier, Molins López-Rodó, Laureano, Mont Girbau, Lluís, Montoro Huguet, Miguel Ángel, Montserrat Canal, Josep M.ª, Morales-Olivas, Francisco José, Morán Chorro, Indalecio, Morata Ruiz, Laura, Morell Brotad, Ferran, Moreno Camacho, M.ª Asunción, Moreno Carriles, Rosa M.ª, Moreno Ramírez, David, Muñoz García, José Esteban, Muñoz García-Paredes, Patricia, Muñoz Gutiérrez, José, Muñoz Mateu, Montserrat, Muñoz Villegas, Álvaro, Muxí Pradas, M.ª África, Navarro Acebes, Xavier, Navasa Anadón, Miquel À., Nicolás Arfelis, José M.ª, Nogué Xarau, Santiago, Nolla Sañas, Joan, Miquel Nolla Solé, Joan, Norman, Francesca F., Obach Baurier, Victor, Obrador Vera, Gregorio Tomás, Oliva Dámaso, Elena, Olivé Marqués, Alejandro, Ordi Ros, José, Ortiz Arduan, Alberto, Ortiz de Lejarazu Leonardo, Raúl, Ortiz Rivera, Marta, Oteo Revuelta, José Antonio, Pablo Rabassó, Joan de, Palau Martínez, Francesc, Pallarés Giner, Román, Palou Rivera, Eduardo, Panés Díaz, Julià, Paré Bardera, Joan Carles, Parés Darnaculleta, Albert, Parrilla Paricio, Pascual, Pascal Capdevila, Mariona, Pascual Gómez, Eliseo, Pascual Gómez, Julio, Pedro-Botet Montoya, Juan, Pedro-Botet Montoya, M.ª Luisa, Pereira Saavedra, Arturo, Pérez Gisbert, Javier, Pérez Jurado, Luis Alberto, Pérez Sáenz, José Luis, Pérez Trallero, Emilio, Picado Vallés, César, Picado de Puig, Albert, Picó Alfonso, Antonio, Pigrau Serrallach, Carlos, Pinazo Delgado, M.ª Jesús, Pintado García, Vicente, Pintos Morell, Guillem, Piñeiro Ibáñez, Daniel José, Poch López de Briñas, Esteban, Pons Lladó, Guillem, Pons-Estel, Bernardo A., Pons-Estel, Guillermo J., Porcel Pérez, José Manuel, Portela Hernández, Margarita, Praga Terente, Manuel, Prat, Aleix, Puig Domingo, Manuel, Pujol Borrell, Ricardo, Pulido Mestre, Marta, Pumarola Suñé, Tomàs, Puras Mallagray, Enrique, Quintana Porras, Luis F., Quintero Carrión, Enrique, Rabinovich, Gabriel A., Rabionet Janssen, Raquel, Ramos Casals, Manuel, Real Arribas, Francisco X., Rego Castro, M.ª José, Reguart, Noemi, Regueiro González, José R., Reverter Calatayud, Jordi Lluís, Reverter Calatayud, Juan Carlos, Rey-Joly Barroso, Celestino, Reyes, José Miguel, Reynals de Blasis, Enrique, Riambau Alonso, Vicente, Ribera Casado, José Manuel, Ribera Santasusana, Josep M.ª, Ribes Rubió, Antonia, Rimola Castellá, Antoni, Río Bueno, Ana del, Robert Boter, Neus, Roca Antònio, Josep, Roca Torrent, Josep, Rodés Teixidor, Joan, Rodríguez Baño, Jesús, Rodríguez de Castro, Felipe, Rodríguez Panadero, Francisco, Rodríguez Pérez, José Carlos, Rodríguez Roisin, Roberto, Roig Minguell, Eulàlia, Rojas García, Ricardo, Romero Gómez, Manuel, Rovira Cañellas, Àlex, Rozman Borstnar, Ciril, Rozman Jurado, María, Ruiz Granell, Ricardo, Ruiz Manzano, Juan, Ruiz Moreno, Javier, Ruiz-Argüelles, Guillermo José, Sabaté Tenas, Manuel, Saiz Hinarejos, Albert, Salgado García, Emilio José, Salinas Vert, Isabel, San Miguel, Jesús F., Sánchez González, Marcelo, Sánchez Rodríguez, Ángel, Sánchez Tapias, José M.ª, Sanmartí Sala, Raimon, Santamaria Cano, Joan, Sanz Alonso, Miguel Ángel, Sanz Santillana, Guillermo F., Saperas Franch, Esteban, Segura Egea, Antonia, Segura Porta, Ferrán, Selva O’Callaghan, Albert, Serra Majem, Lluís, Sierra Gil, Jorge, Sierra Iserte, Alejandro de la, Sierra Romero, Gustavo Adolfo, Sitges Carreño, Marta, Solà Vergés, Elsa, Solana Lara, Rafael, Solans Laqué, Roser, Soldevila Melgarejo, M.ª Gloria, Sopena Galindo, Nieves, Soriano Viladomiu, Álex, Soy Muner, Dolors, Targarona Soler, Eduardo M.ª, Tejedor Jorge, Alberto, Tena Marsà, Xavier, de Teresa Galván, Eduardo, Tolosa Sarró, Eduardo, Tornero Molina, Jesús, Tornos Mas, Pilar, Torra Balcells, Roser, Torre Cisneros, Julián de la, Torregrosa Prats, José Vicente, Torres Hortal, Montserrat, Torres Martí, Antonio, Torres Ramírez, Armando, Torrico, Faustino, Trilla García, Antoni, Tuca Rodríguez, Albert, Tudela Hita, Pere, Urbano Ispizua, Álvaro, Urrutia de Diego, Agustín, Valdés Miyar, Manuel, Valls Lolla, M.ª Eugenia, Valls Solé, Josep, Vaquero Raya, Eva C., Vázquez Martínez, Clotilde, Vázquez Zaragoza, Miguel Ángel, Verea Hernando, Héctor, Vicente García, Vicente, Vidal Bermúdez, José E., Vidal-Puig, Antonio, Vieta Pascual, Eduardo, Vila Estapé, Jordi, Vilar, Eduardo, Vilardell Tarrés, Miguel, Vilella Morató, Anna, Villabona Artero, Carlos, Villamor Casas, Neus, Vinuesa Aumedes, Teresa, Viñolas, Nuria, Vives Corrons, Joan Lluís, Webb Youdale, Susan M., Xaubet Mir, Antonio, Yagüe Ribes, Jordi, and Zarranz Imirizaldu, Juan José
- Published
- 2016
- Full Text
- View/download PDF
16. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.
- Author
-
Ramón Santos, José, Blanco, José Luis, Masiá, Mar, Gutiérrez, Félix, Pérez-Elias, María Jesús, Iribarren, José Antonio, Force, Lluis, Antela, Antonio, Knobel, Hernando, Salavert, Miguel, Bernaldo De Quirós, Juan Carlos López, Pino, María, Paredes, Roger, Clotet, Bonaventura, Santos, José Ramón, Pérez-Elías, María Jesús, López Bernaldo De Quirós, Juan Carlos, and Integrase Resistance Study Group in Spain (INI-VAIN Study Group)
- Subjects
RALTEGRAVIR ,RETROSPECTIVE studies ,DRUG efficacy ,DRUG therapy ,VIROLOGY ,ANTI-HIV agents ,COMPARATIVE studies ,DRUG resistance in microorganisms ,HIV ,HIV infections ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,VIRAL load ,EVALUATION research ,SPECIALTY hospitals ,TREATMENT effectiveness ,DISEASE incidence ,DISEASE prevalence ,GENOTYPES - Abstract
Objectives: The objective of this study was to evaluate the incidence, prevalence and clinical consequences of virological failure (VF) to raltegravir-based regimens in Spain.Methods: A multicentre, retrospective, observational study was performed in 10 tertiary hospitals (January 2006 to June 2013). The study included HIV-1-infected patients with loss of virological suppression (LVS; two consecutive HIV-1 RNA ≥50 copies/mL) while receiving raltegravir. VF and low-level viraemia (LLV) were defined as two consecutive HIV-1 RNA ≥200 copies/mL and 50 to <200 copies/mL, respectively. Integrase strand-transfer inhibitor resistance was investigated at LVS. During the 48 weeks following LVS, recorded data included clinical characteristics, treatment discontinuations, AIDS-associated events and deaths. Effectiveness of therapy following LVS was evaluated by ITT and PP. Multivariate regression was used to assess predictors of efficacy.Results: Of the 15 009 HIV-infected patients in participating centres, 2782 (18.5%) had received raltegravir-based regimens. Of those, 192 (6.9%), 125 (4.5%) and 67 (2.4%) experienced LVS, VF and LLV, respectively. The incidence of VF was 1.8 (95% CI, 1.5-2.1) per 100 patients/year. The prevalence of VF was 4.5% (95% CI, 3.8%-5.3%). Integrase-associated mutations were found in 78.8% of patients with integrase genotyping results available. High-level resistance to dolutegravir was not observed. Salvage therapy failed in 34.1% of patients; progression to AIDS/death occurred in 8.3% during the first year following LVS. The latter was associated with intravenous drug use, time on raltegravir and lower CD4+ count nadir in patients who started raltegravir-based treatments as salvage regimens.Conclusions: VF with raltegravir is infrequent, but often associated with major clinical complications in treatment-experienced patients. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
17. The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens
- Author
-
Gómez, Carmen Elena, primary, Nájera, José Luis, additional, Perdiguero, Beatriz, additional, García-Arriaza, Juan, additional, Sorzano, Carlos Oscar S., additional, Jiménez, Victoria, additional, González-Sanz, Rubén, additional, Jiménez, José Luis, additional, Muñoz-Fernández, María Angeles, additional, López Bernaldo de Quirós, Juan Carlos, additional, Guardo, Alberto C., additional, García, Felipe, additional, Gatell, José M., additional, Plana, Montserrat, additional, and Esteban, Mariano, additional
- Published
- 2011
- Full Text
- View/download PDF
18. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza
- Author
-
Alonso, María, primary, Rodríguez-Sánchez, Belén, additional, Giannella, Maddalena, additional, Catalán, Pilar, additional, Gayoso, Jorge, additional, López Bernaldo de Quirós, Juan Carlos, additional, Bouza, Emilio, additional, and de Viedma, Darío García, additional
- Published
- 2011
- Full Text
- View/download PDF
19. The Eldest of Older Adults Living with HIV: Response and Adherence to Highly Active Antiretroviral Therapy
- Author
-
Brañas, Fátima, primary, Berenguer, Juan, additional, Sánchez-Conde, Matilde, additional, López-Bernaldo de Quirós, Juan Carlos, additional, Miralles, Pilar, additional, Cosín, Jaime, additional, and Serra, José Antonio, additional
- Published
- 2008
- Full Text
- View/download PDF
20. Diagnóstico microbiológico de la infección por el VIH
- Author
-
López-Bernaldo de Quirós, Juan Carlos, primary, Delgado, Rafael, additional, García, Federico, additional, Eiros, José M.ª, additional, and de Lejarazu, Raúl Ortiz, additional
- Published
- 2007
- Full Text
- View/download PDF
21. Immunotherapy and therapeutic vaccines in HIV infection
- Author
-
García, Felipe, primary, Ruiz, Lidia, additional, López-Bernaldo de Quirós, Juan Carlos, additional, Moreno, Santiago, additional, and Domingo, Pere, additional
- Published
- 2005
- Full Text
- View/download PDF
22. Inmunoterapia y vacunas terapéuticas en la infección por VIH
- Author
-
García, Felipe, primary, Ruiz, Lidia, additional, López-Bernaldo de Quirós, Juan Carlos, additional, Moreno, Santiago, additional, and Domingo, Pere, additional
- Published
- 2005
- Full Text
- View/download PDF
23. Motivos de introducción de darunavir en un régimen antirretroviral en pacientes infectados por el virus de la inmunodeficiencia adquiridaS.
- Author
-
Pedrol, Enric, López-Bernaldo de Quirós, Juan Carlos, Ruiz, Sheila, Hevia, Henar, and Ledesma, Francisco
- Subjects
DARUNAVIR ,DRUG delivery systems ,HIV infections ,THERAPEUTICS ,ACQUISITION of data ,CROSS-sectional method - Abstract
Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2013
24. Estudio comparativo a largo plazo de la función renal en pacientes con infección VIH tratados con tenofovir disoproxil fumarato
- Author
-
Maestro de la Calle, Guillermo, Palacio Pérez-Medel, Ángel del, López Bernaldo de Quirós, Juan Carlos, and Pulido Ortega, Federico
- Subjects
Nefrología y urología ,Enfermedades infecciosas - Published
- 2015
25. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
- Author
-
Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, and Plana M
- Subjects
- AIDS Vaccines adverse effects, Antibodies, Neutralizing immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, HIV Antibodies blood, Healthy Volunteers, Humans, Placebos, AIDS Vaccines immunology, HIV-1 immunology, Immunization, Secondary
- Abstract
Background: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost., Methods: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost., Results: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively., Conclusions: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector., Trial Registration: ClinicalTrials.gov NCT01923610.
- Published
- 2017
- Full Text
- View/download PDF
26. [Tenofovir DF in rescue regimens].
- Author
-
López Bernaldo de Quirós JC
- Subjects
- Adenine administration & dosage, Adenine pharmacology, Adenine therapeutic use, Anti-HIV Agents administration & dosage, Anti-HIV Agents classification, Anti-HIV Agents pharmacology, Antimetabolites pharmacology, Clinical Trials, Phase III as Topic statistics & numerical data, Drug Therapy, Combination, HIV genetics, HIV Reverse Transcriptase genetics, Humans, Multicenter Studies as Topic, Mutation, Organophosphonates administration & dosage, Organophosphonates pharmacology, Randomized Controlled Trials as Topic statistics & numerical data, Retrospective Studies, Reverse Transcriptase Inhibitors administration & dosage, Reverse Transcriptase Inhibitors pharmacology, Selection, Genetic, Tenofovir, Thymidine analogs & derivatives, Treatment Failure, Viral Load, Zalcitabine administration & dosage, Zalcitabine pharmacology, Zalcitabine therapeutic use, Adenine analogs & derivatives, Anti-HIV Agents therapeutic use, Drug Resistance, Multiple, Viral genetics, HIV enzymology, HIV Infections drug therapy, HIV Reverse Transcriptase antagonists & inhibitors, Organophosphonates therapeutic use, Reverse Transcriptase Inhibitors therapeutic use, Salvage Therapy
- Abstract
As with other nucleoside analogues, tenofovir (TDF) can be affected by several mutations in the reverse transcriptase gene. Most nucleoside analogue mutations (NAMs) are not induced specifically by TDF, although they can affect the activity of this drug. The impact of thymidine analogue mutations (TAMs) on tenofovir varies and, as with the remaining nucleoside analogue reverse transcriptase inhibitors, largely depends on the type and number present. Thus, the greater the number of TAMs, and the greater the number of type 1 TAMs, the more TDF activity will be affected. The 41L and 210W mutations have the greatest effect. The incidence of the 65R mutation was slight before the clinical introduction of TDF. This mutation was selected by treatments with zalcitabine monotherapy. However, after TDF came on to the market, the 65R mutation began to be more frequently reported and is currently the signature mutation of this drug. TDF has been shown to be safe and effective in patients with prior virological failure and resistance mutations in the reverse transcriptase gene. In these patients, the presence of the 41L and 210W mutations is associated with a worse response to rescue therapy containing TDF. In contrast, the presence of type 2 TAMs (67N, 70R and 219Q/E/N) has little effect on TDF activity in these patients. Importantly, in TDF therapy, the presence of the 184V mutation is associated with a more favorable virologic response than the absence of this mutation, with any of the distinct combinations of mutations present.
- Published
- 2008
- Full Text
- View/download PDF
27. [Microbiological diagnosis of HIV infection].
- Author
-
López-Bernaldo de Quirós JC, Delgado R, García F, Eiros JM, and Ortiz de Lejarazu R
- Subjects
- AIDS Serodiagnosis methods, AIDS Serodiagnosis standards, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, Blotting, Western, Drug Resistance, Viral genetics, Genotype, HIV Infections blood, HIV Infections epidemiology, HIV Infections virology, HIV-1 drug effects, HIV-1 genetics, HIV-1 immunology, Humans, Internal Medicine, Mass Screening, Microbiology, Practice Guidelines as Topic, Societies, Medical, Spain epidemiology, Specimen Handling methods, Specimen Handling standards, Viral Load, Viremia diagnosis, HIV Infections diagnosis, HIV-1 isolation & purification
- Abstract
Currently, there are around 150,000 HIV-infected patients in Spain. This number, together with the fact that this disease is now a chronic condition since the introduction of antiretroviral therapy, has generated an increasing demand on the clinical microbiology laboratories in our hospitals. This increase has occurred not only in the diagnosis and treatment of opportunistic diseases, but also in tests related to the diagnosis and therapeutic management of HIV infection. To meet this demand, the Sociedad de Enfermedades Infecciosas y Microbiología Clinica (Spanish Society of Infectious Diseases and Clinical Microbiology) has updated its standard Procedure for the microbiological diagnosis of HIV infection. The main advances related to serological diagnosis, plasma viral load, and detection of resistance to antiretroviral drugs are reviewed in this version of the Procedure.
- Published
- 2007
- Full Text
- View/download PDF
28. Clinical impact of a 5-day versus 7-day blood culture incubation period.
- Author
-
López Bernaldo De Quirós JC, Sánchez-Carrillo C, Cercenado E, Fron C, Catalán P, and Bouza E
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.